866-997-4948(US-Canada Toll Free)

Hairy Cell Leukemia - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 89 Pages

Hairy Cell Leukemia - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hairy Cell Leukemia - Pipeline Review, H1 2017, provides an overview of the Hairy Cell Leukemia (Oncology) pipeline landscape.

Hairy cell leukemia is a rare, slow-growing cancer of the blood in which bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. Symptoms include fatigue, easy bruising, recurring infections, weakness and weight loss. Risk factors include exposure to radiation, chemicals and saw dust. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hairy Cell Leukemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hairy Cell Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hairy Cell Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Hairy Cell Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 2, 1, 3 and 1 respectively.

Hairy Cell Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hairy Cell Leukemia (Oncology).
- The pipeline guide reviews pipeline therapeutics for Hairy Cell Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hairy Cell Leukemia (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hairy Cell Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hairy Cell Leukemia (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hairy Cell Leukemia (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hairy Cell Leukemia (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hairy Cell Leukemia - Overview
Hairy Cell Leukemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hairy Cell Leukemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hairy Cell Leukemia - Companies Involved in Therapeutics Development
AbbVie Inc
ARA Healthcare Pvt Ltd
Astellas Pharma Inc
Cellectis SA
F. Hoffmann-La Roche Ltd
Incyte Corp
Juno Therapeutics Inc
MedImmune LLC
Novartis AG
Hairy Cell Leukemia - Drug Profiles
AGS-67E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARABS-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dezapelisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibrutinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCB-50465 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon alfa-2a - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon alfa-2b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itacitinib adipate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
moxetumomab pasudotox - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UCART-123 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vadacabtagene leraleucel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vemurafenib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hairy Cell Leukemia - Dormant Projects
Hairy Cell Leukemia - Discontinued Products
Hairy Cell Leukemia - Product Development Milestones
Featured News & Press Releases
Oct 09, 2016: ESMO 2016: Vemurafenib Shows Clinical Benefit in Diverse BRAF V600-Mutated Tumours
May 16, 2013: AstraZeneca's MedImmune Enrolls First Patient In Phase III Leukemia Trial Of Moxetumomab Pasudotox
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hairy Cell Leukemia, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Hairy Cell Leukemia - Pipeline by AbbVie Inc, H1 2017
Hairy Cell Leukemia - Pipeline by ARA Healthcare Pvt Ltd, H1 2017
Hairy Cell Leukemia - Pipeline by Astellas Pharma Inc, H1 2017
Hairy Cell Leukemia - Pipeline by Cellectis SA, H1 2017
Hairy Cell Leukemia - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Hairy Cell Leukemia - Pipeline by Incyte Corp, H1 2017
Hairy Cell Leukemia - Pipeline by Juno Therapeutics Inc, H1 2017
Hairy Cell Leukemia - Pipeline by MedImmune LLC, H1 2017
Hairy Cell Leukemia - Pipeline by Novartis AG, H1 2017
Hairy Cell Leukemia - Dormant Projects, H1 2017
Hairy Cell Leukemia - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Hairy Cell Leukemia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *